<DOC>
	<DOCNO>NCT00935246</DOCNO>
	<brief_summary>To reveal genetic determinant treatment outcome escitalopram depress patient ( use candidate gene approach whole genome scanning ) .</brief_summary>
	<brief_title>Development Escitalopram Genomic Device Using Candidate Gene Approach Genome-Wide Scanning</brief_title>
	<detailed_description>The purpose study : 1 . To reveal genetic determinant treatment outcome escitalopram depress patient ( use candidate gene approach whole genome scanning ) 2 . To improve success rate escitalopram treatment response depress patient</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Eligible patient enrol clinical trial program hte Samsung Medical Center Geropsychiatry Affective Disorder Clinics ( Seoul , Korea ) . They receive semistructured diagnostic interview , Samsung Psychiatric Evaluation Schedule . The affective disorder section Samsung Psychiatric Evaluation Schedule use Korean version structure clinical interview diagnostic statistical manual mental disorder , Fourth edition . 2. interview one patient 's family member objective diagnosis final diagnosis decision agreement two psychiatric physician 1. receive psychotropic medication within 2 week study fluoxetine within 4 week 2. potential study participant pregnancy , significant medical condition , abnormal laboratory baseline value , unstable psychiatric feature ( eg.suicidal ) , history alcohol drug dependence , seizure , head trauma loss consciousness , neurological illness , concomitant Axis I psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Genomic device</keyword>
	<keyword>Prediction Escitalopram Response</keyword>
	<keyword>Depressed Patients</keyword>
</DOC>